Centre Number
Candidate Number
*P67102A0128*
Turn over    
Total Marks
Candidate surname
Other names
Please check the examination details below before entering your candidate information
Paper
reference


Pearson Edexcel International Advanced Level
Time 1 hour 30 minutes
WBI11/01
Biology
Advanced Subsidiary
Unit 1: Molecules, Diet, Transport and Health
You must have:
Scientific calculator, ruler, HB pencil
Instructions
•	Use black ink or ball-point pen.
•	Fill in the boxes at the top of this page with your name,  
centre number and candidate number.
•	Answer all questions.
•	Answer the questions in the spaces provided  
– there may be more space than you need.
•	Calculators may be used.
•	You must show all your working out with your answer clearly identified at the 
end of your solution.
Information
•	The total mark for this paper is 80.
•	The marks for each question are shown in brackets  
– use this as a guide as to how much time to spend on each question.
•	Any diagrams may NOT be accurately drawn, unless otherwise indicated.
•	In questions marked with an asterisk (*), marks will be awarded for your ability to 
structure your answer logically showing how the points that you make are related 
or follow on from each other where appropriate.
Advice
•	Read each question carefully before you start to answer it.
•	Try to answer every question.
•	Check your answers if you have time at the end.
P67102A
©2021 Pearson Education Ltd.
E:1/1/1/1/
PMT


--- Page Break ---

*P67102A0228*
2
	
 
 
SECTION A
Answer ALL questions. Write your answers in the spaces provided.
Some questions must be answered with a cross in a box . If you change your mind about an 
answer, put a line through the box 
 and then mark your new answer with a cross .
1	 Mutations can give rise to cancer.
	
(a)	 What is a mutation?
(1)
	
A	 a change in the amino acid sequence in DNA
	
B	 a change in the amino acid sequence in a protein
	
C	 a change in the base sequence in DNA
	
D	 a change in the base sequence in a protein
	
(b)	 Name two types of mutation.
(1)
1.................................................................................................................................................................................................................................................................................
2.................................................................................................................................................................................................................................................................................
PMT


--- Page Break ---

*P67102A0328*
Turn over    
3
	
 
 
	
(c)	 The graph shows the number of cases of one type of cancer in a 
human population.
4000
3000
2000
1000
0
90
80
70
60
50
40
30
20
10
0
Age / years
Number of cases of 
cancer per 100 000 
population
Key
Male	
Female	
	
	
Describe the effect of age and sex on the number of cases of cancer.
(3)
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
(Total for Question 1 = 5 marks)
PMT


--- Page Break ---

*P67102A0428*
4
	
 
 
2	 Warfarin is a drug used to treat people who have a blood clot.
	
(a)	 (i)	 Read through the following passage about warfarin.
	
	
	
Write on the dotted lines the most appropriate word or words to complete 
the passage.
(3)
	
	
	
Warfarin is used to treat people with blood clots as it lowers the number of 
clotting factors in the blood.
	
	
	
One clotting factor in blood is prothrombin.
	
	
	
Prothrombin is converted to the enzyme thrombin by ..............................................................  
	
	
	
The .............................................................. of thrombin binds to fibrinogen and as a result a 
 
mesh of fibres and .............................................................. is formed.
	
	
(ii)	 Which type of drug is warfarin?
(1)
	
A	 an anticoagulant
	
B	 an antihypertensive
	
C	 a platelet inhibitor
	
D	 a statin
PMT


--- Page Break ---

*P67102A0528*
Turn over    
5
	
 
 
	
(b)	 The time taken for a blood sample to form a blood clot can be measured. This is 
called the clotting time.
	
	
The graph shows the blood clotting time after a patient has stopped 
taking warfarin.
35
30
25
20
15
10
5
0
8
7
6
5
4
3
2
1
0
Time after the patient stopped taking warfarin / days
Blood clotting 
time / s
	
	
Calculate the rate of decrease in the clotting time at two days after stopping 
taking warfarin. 
	
	
Use a tangent for your calculation.
(2)
Answer ..............................................................
(Total for Question 2 = 6 marks)
PMT


--- Page Break ---

*P67102A0628*
6
	
 
 
3	 Many animals have a heart and circulation.
	
(a)	 The diagram shows the structure of a human heart.
	
	
Label the diagram with the names of the four major blood vessels.
(3)
............................................................................................
............................................................................................
............................................................................................
............................................................................................
	
(b)	 The table shows some structures and the types of blood vessel that they are 
found in.
	
Put a cross  in each row to show where these structures are found.
(3)
Structures
Found in 
arteries only
Found in 
capillaries only
Found in  
veins only
Found in 
arteries, 
capillaries and 
veins
Lining of 
endothelial cells 
Valves along the 
length of the 
blood vessel
Wall only one cell 
thick 
PMT


--- Page Break ---

*P67102A0728*
Turn over    
7
	
 
 
	
(c)	 The graph shows the velocity of the blood as it flows through the arteries into the 
capillaries and then into the veins.
large  
arteries
small  
arteries
arterioles
capillaries
venules
veins
artery
arterioles
capillaries
venules
vein
Velocity of 
blood flow
	
	
Describe the changes in the velocity of the blood as it flows from an artery to 
a vein.
(3)
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
(Total for Question 3 = 9 marks)
PMT


--- Page Break ---

*P67102A0828*
8
	
 
 
4	 The butterfly is an insect that feeds on nectar produced by flowers.
	
The photograph shows a butterfly feeding on a flower. 
(Source: James Schwabel / Alamy Stock Photo)
	
(a)	 The nectar in flowers contains nutrients including sugars, amino acids and lipids.
	
	
(i)	 The sugars in the nectar are fructose, glucose and sucrose.
	
	
	
Which of these contain glycosidic bonds?
(1)
	
A	 fructose only
	
B	 sucrose only
	
C	 fructose and glucose
	
D	 fructose and sucrose
PMT


--- Page Break ---

*P67102A0928*
Turn over    
9
	
 
 
	
	
(ii)	 Which row of the table describes how amino acids are joined together to form 	
a protein?	
(1)
name of bond
type of reaction
A
ester
condensation
B
ester
hydrolysis
C
peptide
condensation
D
peptide
hydrolysis
	
	
(iii)	Which row of the table describes a saturated lipid?
(1)
carbon-carbon double bonds
carbon : hydrogen ratio
A
absent
higher than in an unsaturated 
fatty acid chain
B
absent
lower than in an unsaturated 
fatty acid chain
C
present
higher than in an unsaturated 
fatty acid chain
D
present
lower than in an unsaturated 
fatty acid chain
PMT


--- Page Break ---

*P67102A01028*
10
	
 
 
	
(b)	 The circulatory system of an insect is described as an open system. This means 	
that the blood is not contained inside blood vessels but flows through cavities 	
called sinuses.
	
	
The diagram shows part of the circulatory system of an insect.
Head
Abdomen
Thorax
Conducting vessel: blood flows out of the 
conducting vessel into spaces 
within the body called sinuses
Heart: pumps blood from the 
abdomen towards the head
Sinuses: blood flows over the 
organs and drains 
back into the heart
PMT


--- Page Break ---

*P67102A01128*
Turn over    
11
	
 
 
	
	
(i)	 The length of the head of a butterfly is 4 mm, the thorax is 6 mm and the 
abdomen is 18 mm.
	
	
	
Estimate the surface area to volume ratio of the butterfly. 
	
	
	
Assume that the insect is a cylinder of diameter 4 mm and the surface area 
is 360 mm2.
(2)
Answer ..............................................................
	
	
(ii)	 Explain why the circulation of a butterfly is different from the circulation of 
a mammal.
(2)
.....................................................................................................................................................................................................................................................................................
.....................................................................................................................................................................................................................................................................................
.....................................................................................................................................................................................................................................................................................
.....................................................................................................................................................................................................................................................................................
.....................................................................................................................................................................................................................................................................................
.....................................................................................................................................................................................................................................................................................
	
	
(iii)	The blood flowing through the sinuses of the butterfly is separated from the 
organs by collagen.
	
	
	
Describe the structure of collagen.
(2)
.....................................................................................................................................................................................................................................................................................
.....................................................................................................................................................................................................................................................................................
.....................................................................................................................................................................................................................................................................................
.....................................................................................................................................................................................................................................................................................
.....................................................................................................................................................................................................................................................................................
.....................................................................................................................................................................................................................................................................................
(Total for Question 4 = 9 marks)
PMT


--- Page Break ---

*P67102A01228*
12
	
 
 
5	 Genetic screening can be used to test for aneuploidy.
	
Aneuploidy is the presence of an abnormal number of chromosomes in a cell.
	
Aneuploidy can affect the miscarriage rate of implanted embryos. 
	
Following screening, only embryos with the correct number of chromosomes are 	
implanted into the female. 
	
The table shows the miscarriage rate of two groups of implanted embryos:
•	
embryos not screened for aneuploidy 
•	
embryos screened and shown not to have aneuploidy.
Age range 
of women at 
implantation / years
Miscarriage rate (%)
Implanted embryos 
not screened for 
aneuploidy
Implanted embryos 
screened and shown 
not to have aneuploidy
<35
12.0
11.2
35 to 37
16.8
13.0
38 to 40
25.0
13.6
41 to 42
37.9
16.3
>42
58.8
17.2
	
(a)	 Explain how this data shows that there is a correlation between the age of the 
women and the miscarriage rate.
(2)
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
PMT


--- Page Break ---

*P67102A01328*
Turn over    
13
	
 
 
	
(b)	 (i)	 Explain the conclusions that can be made from these data about the causes 
of miscarriage.
(2)
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
	
	
(ii)	 Explain why conclusions made using these data may not be valid.
(3)
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
PMT


--- Page Break ---

*P67102A01428*
14
	
 
 
	
(c)	 Discuss the implications of screening embryos for aneuploidy before implantation.
(3)
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
(Total for Question 5 = 10 marks)
PMT


--- Page Break ---

*P67102A01528*
Turn over    
15
	
 
 
6	 Acute hepatic porphyria (AHP) is a very rare genetic disorder.
	
A drug has been developed to treat AHP.
	
(a)	 This drug was tested in a clinical trial involving 94 patients from 18 countries.
	
	
The drug was given to 48 of the patients. The other 46 patients were a 
control group.
	
	
(i)	 Comment on the design of this clinical trial.
(2)
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
	
	
(ii)	 Each patient was given 2.5 mg of the drug per kg of body mass, once a month.
	
	
	
The drug is available as a solution with a concentration of 189 mg cm−3.
	
	
	
Calculate the volume of drug that was given each month to a patient with a 
body mass of 64 kg.
(2)
Answer ..............................................................
PMT


--- Page Break ---

*P67102A01628*
16
	
 
 
	
	
(iii)	Nausea was experienced by 27% of the patients receiving this drug.
	
	
	
Calculate the number of patients who experienced nausea.
(2)
Answer ..............................................................
PMT


--- Page Break ---

*P67102A01728*
Turn over    
17
	
 
 
	
(b)	 This drug is a double-stranded RNA molecule.
	
	
(i)	 The diagram shows part of the base sequence on one of the RNA strands.
	
	
	
Complete the diagram to show the base sequence on the other RNA strand.
(2)
C
A
G
A
A
A
G
	
	
(ii)	 Describe the bonding in this double-stranded RNA molecule. 
(3)
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
PMT


--- Page Break ---

*P67102A01828*
18
	
 
 
	
	
(iii)	In AHP, toxic porphyrin molecules build up.
	
	
	
The synthesis of the haem component of haemoglobin involves several steps. 
	
	
	
Each step in the synthesis of haem is catalysed by a different enzyme.
	
	
	
This drug works by interfering with the mRNA copies from the gene coding 
for one of these enzymes.
	
	
	
Explain how the action of this drug helps patients with AHP.
(3)
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
(Total for Question 6 = 14 marks)
PMT


--- Page Break ---

*P67102A01928*
Turn over    
19
	
 
 
BLANK PAGE
PMT


--- Page Break ---

*P67102A02028*
20
	
 
 
7	 A number of factors affect the risk of a person developing heart disease.
	
One factor affecting this risk is the level of high-density lipoprotein (HDL) in the blood.
	
 *(a)	 The graph shows the effects of HDL levels and low-density lipoprotein (LDL) levels 
in the blood on the risk of men developing heart disease.
Risk of heart 
disease in men
LDL level in blood
HDL = 63.0 mmol dm−3
HDL = 82.5 mmol dm−3
HDL = 43.5 mmol dm−3
HDL = 24.4 mmol dm−3
PMT


--- Page Break ---

*P67102A02128*
Turn over    
21
	
 
 
	
	
For men, a blood HDL level greater than 40 mg dm−3 is thought to be optimal.
	
	
Explain why a man with a blood HDL level greater than 40 mg dm−3 may still have 
a high risk of developing heart disease.
	
	
Use the information in the graph and your own knowledge to support 
your answer.
(6)
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
PMT


--- Page Break ---

*P67102A02228*
22
	
 
 
	
(b)	 Very high levels of cholesterol in the blood can alter the structure of HDL. 
This altered HDL is less effective in reducing the risk of heart disease.
	
	
The diagram shows the structure of HDL in blood with a low level of cholesterol 
and altered HDL in blood with a high level of cholesterol.
ApoA-1
ApoM
ApoA-1
RBP4
CRABP1
Key
long-chain polyunsaturated PC
CE
protein
HDL
altered HDL
phospholipid 
layer
(Source: https://www.sciencedirect.com/science/article/pii/S0735109717373448)
	
 	
(i)	 Compare and contrast the structure of HDL with altered HDL.
(3)
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
PMT


--- Page Break ---

*P67102A02328*
Turn over    
23
	
 
 
	
	
(ii)	 The antioxidant properties of altered HDL are reduced.
	
	
	
Explain the effect that this has on reducing the risk of heart disease.
(3)
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
(Total for Question 7 = 12 marks)
PMT


--- Page Break ---

*P67102A02428*
24
	
 
 
8	 The drawing shows a speckled chicken. These chickens have a mixture of black and 
white feathers.
	
The colour of the feathers of a chicken is an example of codominance. 
	
One parent of this speckled chicken had white feathers and the other parent had 
black feathers.
	
(a)	 Describe the difference between each of the following pairs of terms, using 
feather colour to illustrate your answer.
	
	
(i)	 Gene and allele
(3)
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
PMT


--- Page Break ---

*P67102A02528*
Turn over    
25
	
 
 
	
	
(ii)	 Genotype and phenotype
(3)
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
	
(b)	 A black chicken was mated with a speckled chicken. They had 25 chicks.
	
	
Determine the expected number of speckled chicks.
	
	
You must use a genetic diagram.
(3)
Answer ..............................................................
PMT


--- Page Break ---

*P67102A02628*
26
	
 
 
	
(c)	 In an experiment, several pairs of speckled chickens were mated together.
	
	
They produced 480 chicks.
	
	
The table shows the expected number of speckled chicks, white chicks and black 
chicks. It also shows the actual number of each type of chick. 
Steps in the calculation 
for the statistics test
Colour of feathers of chicks
Speckled
White
Black
Observed number (O)
243
125
112
Expected number (E)
240
120
120
(O-E)
(O-E
E
)2
	
	
This table can be used in a statistics test.
	
	
(i)	 Name the statistics test being used to analyse these data.
(1)
....................................................................................................................................................................................................................................................................................
	
	
(ii)	 Complete this table to show the missing values.
(2)
	
	
(iii)	Calculate  
(O-E
E
)2
∑
(1)
Answer ..............................................................
PMT


--- Page Break ---

*P67102A02728*
27
	
 
 
	
	
(iv)	Explain how a critical value table could be used to accept or reject a null 
hypothesis for this experiment.
(2)
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
....................................................................................................................................................................................................................................................................................
(Total for Question 8 = 15 marks)
TOTAL FOR PAPER = 80 MARKS
PMT


--- Page Break ---

*P67102A02828*
28
	
 
 
BLANK PAGE
PMT
